Skip to content
Screener

Neurocrine Biosciences NBIX Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$5.09M+1,613%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$16.08M+30.7%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$814.5M+42.2%
Gross profit$800.7M+42.1%
Operating income$193.4M+719%
Net income$197.9M+2,405%
EPS (diluted)$1.91+2,287%

Balance sheet

See full
Cash & equivalents$274.5M+35.8%
Total debt$463.5M-6.0%
Total equity$3.4B+34.4%
Total assets$4.9B+33.0%

Cash flow

See full
Operating cash flow$145.8M+125%
CapEx$9.1M-15.0%
Free cash flow$136.7M+153%

Valuation

See full
Market cap$16.61B+35.1%
Enterprise value$16.8B+34.2%
P/E24.8×-10.5×
P/S5.4×+0.5×

Profitability

See full
Gross margin98.2%-0.3pp
Operating margin25.4%+4.9pp
Net margin21.6%+8.9pp
FCF margin26.8%+6.4pp

Returns & leverage

See full
Return on equity22.5%+10.1pp
Debt / equity0.1×-0.1×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000914475-26-000026
(in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of available-for-sale debt securities(819.5)(273.2)
Sales and maturities of available-for-sale debt securities259.2298.1
Proceeds from sale of business63.2
Capital expenditures(9.1)(10.7)
Cash flows from investing activities(506.2)14.2
Cash flows from financing activities:
Issuances of common stock under benefit plans23.632.1
Taxes paid related to net share settlement of equity awards(55.7)

Item 1. Financial Statements

FAQ

What is Neurocrine Biosciences's payments to acquire property, plant, and equipment?
Neurocrine Biosciences (NBIX) reported payments to acquire property, plant, and equipment of $9.1M in Q1 2026.
How has Neurocrine Biosciences's payments to acquire property, plant, and equipment changed year-over-year?
Neurocrine Biosciences's payments to acquire property, plant, and equipment decreased by 15.0% year-over-year, from $10.7M to $9.1M.
What is the long-term trend for Neurocrine Biosciences's payments to acquire property, plant, and equipment?
Over 3 years (2021 to 2025), Neurocrine Biosciences's payments to acquire property, plant, and equipment has grown at a 15.9% compound annual growth rate (CAGR), from $23.4M to $36.4M.

Ask your AI about Neurocrine Biosciences's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude